Sofosbuvir shows promise for chronic hepatitis C infection

Sofosbuvir shows promise for chronic hepatitis C infection
Sofosbuvir seems to be a promising treatment option for patients with chronic hepatitis C virus infection, according to two studies published online April 23 in the New England Journal of Medicine to coincide with presentation at The International Liver Congress, the annual meeting of the European Association for the Study of the Liver, held from April 24 to 28 in Amsterdam.

(HealthDay)—Sofosbuvir seems to be a promising treatment option for patients with chronic hepatitis C virus (HCV) infection, according to two studies published online April 23 in the New England Journal of Medicine to coincide with presentation at The International Liver Congress, the annual meeting of the European Association for the Study of the Liver, held from April 24 to 28 in Amsterdam.

Ira M. Jacobson, M.D., from Weill Cornell Medical College in New York, and colleagues conducted two randomized phase 3 studies involving patients with chronic HCV genotype 2 or 3. The researchers found that the rate of sustained was 78 percent with sofosbuvir and ribavirin versus 0 percent with placebo in patients for whom peginterferon treatment was not an option. For previously treated non-responders, the rate of response with sofosbuvir and ribavirin was 50 percent at 12 weeks and 73 percent at 16 weeks.

Eric Lawitz, M.D., from the Texas Liver Institute in San Antonio, and colleagues conducted two phase 3 studies in previously untreated patients with HCV. The researchers found that in a single-group study the sustained virologic response was 90 percent with a 12-week regimen of sofosbuvir plus peginterferon alfa-2a and ribavirin. In the non-inferiority trial, the sustained virologic response was 67 percent for patients treated with 12 weeks of sofosbuvir plus ribavirin and 67 percent for those treated with 24 weeks of -2a plus ribavirin.

"The data from the sofosbuvir trials suggest that a radical change in clinical practice is imminent," write the authors of an accompanying editorial.

Several authors from the Jacobson study disclosed financial ties to pharmaceutical companies, including Gilead Sciences, which manufactures sofosbuvir and funded both studies.

More information: Full Text - Jacobson
Full Text - Lawitz
Editorial
More Information

Related Stories

New treatment therapy helps inhibit hepatitis C

Jul 31, 2008

Two new studies examine the use of the nucleoside polymerase inhibitor, R1626, to the standard therapy for hepatitis C. The reports appear in the August issue of Hepatology, a journal published by John Wiley & Sons on beh ...

Coffee drinking improves hepatitis C treatment response

Jun 07, 2011

Advanced hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) ...

Recommended for you

Vietnam battles fatal measles outbreak

1 hour ago

Vietnam is scrambling to contain a deadly outbreak of measles that has killed more than 100 people, mostly young children, and infected thousands more this year, the government said Friday.

Researchers discover target for treating dengue fever

18 hours ago

Two recent papers by a University of Colorado School of Medicine researcher and colleagues may help scientists develop treatments or vaccines for Dengue fever, West Nile virus, Yellow fever, Japanese encephalitis and other ...

User comments